JP2016527284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527284A5 JP2016527284A5 JP2016532244A JP2016532244A JP2016527284A5 JP 2016527284 A5 JP2016527284 A5 JP 2016527284A5 JP 2016532244 A JP2016532244 A JP 2016532244A JP 2016532244 A JP2016532244 A JP 2016532244A JP 2016527284 A5 JP2016527284 A5 JP 2016527284A5
- Authority
- JP
- Japan
- Prior art keywords
- intra
- pharmaceutical formulation
- pepstatin
- prodrugs
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229950000964 pepstatin Drugs 0.000 claims 5
- 108010091212 pepstatin Proteins 0.000 claims 5
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 208000036487 Arthropathies Diseases 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 208000012659 Joint disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010007710 Cartilage injury Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000004963 pathophysiological condition Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003923.3 | 2013-08-06 | ||
| EP13003923 | 2013-08-06 | ||
| PCT/EP2014/001861 WO2015018472A1 (de) | 2013-08-06 | 2014-07-07 | Intraartikuläre applikation von pepstatin bei arthrose |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527284A JP2016527284A (ja) | 2016-09-08 |
| JP2016527284A5 true JP2016527284A5 (enExample) | 2017-08-17 |
| JP6336067B2 JP6336067B2 (ja) | 2018-06-06 |
Family
ID=48948200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532244A Expired - Fee Related JP6336067B2 (ja) | 2013-08-06 | 2014-07-07 | 関節症の場合のペプスタチンの関節内適応 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9750784B2 (enExample) |
| EP (1) | EP3030250B1 (enExample) |
| JP (1) | JP6336067B2 (enExample) |
| CN (1) | CN105451754A (enExample) |
| AU (1) | AU2014304950B2 (enExample) |
| CA (1) | CA2920420C (enExample) |
| ES (1) | ES2759060T3 (enExample) |
| IL (1) | IL243983B (enExample) |
| WO (1) | WO2015018472A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020235567A1 (ja) * | 2019-05-21 | 2020-11-26 | 国立大学法人 東京大学 | 脳腫瘍の検出用蛍光プローブ |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906085A (en) * | 1973-05-21 | 1975-09-16 | Lilly Co Eli | Determination of hypertension associated with elevated renin levels |
| CA1286846C (en) | 1985-02-12 | 1991-07-23 | Catherine Cazaubon | Peptide derivatives which inhibit renin and acid proteases |
| US6251928B1 (en) | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| JP2001510474A (ja) | 1997-02-04 | 2001-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | カテプシンｄのナノモルの非ペプチド阻害剤 |
| US5962506A (en) | 1997-07-07 | 1999-10-05 | Pharmacopeia, Inc. | Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases |
| US5986102A (en) | 1998-04-29 | 1999-11-16 | Pharmacopeia, Inc. | Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases |
| JP2000300266A (ja) | 1999-04-20 | 2000-10-31 | St Marianna Univ School Of Medicine | ポリペプチド及びｄｎａ |
| CA2489095A1 (en) | 2002-06-17 | 2003-12-24 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| JP4448134B2 (ja) | 2003-08-08 | 2010-04-07 | シェーリング コーポレイション | ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤 |
| EP1654380A4 (en) * | 2003-08-14 | 2009-09-09 | Insight Biopharmaceuticals Ltd | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF |
| GB0325830D0 (en) | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| US20050239836A1 (en) | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
| CA2558249A1 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors |
| EP1851208A1 (en) | 2005-01-13 | 2007-11-07 | Novartis AG | Macrocyclic compounds useful as bace inhibitors |
| CN101193892A (zh) | 2005-06-14 | 2008-06-04 | 先灵公司 | 大环杂环天冬氨酰基蛋白酶抑制剂 |
| US20070021413A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Diamino alcohols as therapeutic compounds |
| US20070021400A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Amino alcohols as therapeutic compounds |
| US20070021399A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Amido-amino alcohols as therapeutic compounds |
| GB0526614D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| EP1867329A3 (en) | 2006-06-14 | 2008-05-07 | Speedel Experimenta AG | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds |
| EP1872780A3 (en) | 2006-06-14 | 2008-04-30 | Speedel Experimenta AG | Omega-Phenyloctanamides as therapeutic compounds |
| EP1987834A3 (en) | 2007-02-13 | 2008-11-19 | Speedel Experimenta AG | Substituted piperidines as therapeutic compounds |
| WO2008119772A1 (en) | 2007-03-30 | 2008-10-09 | Medivir Ab | Amide derivatives as inhibitors of aspartyl proteases |
| WO2009013293A1 (en) | 2007-07-24 | 2009-01-29 | Novartis Ag | Substituted cyclohexanecarboxamides useful as bace inhibitors |
| CA2826622C (en) * | 2011-02-08 | 2021-03-02 | Merck Patent Gmbh | Aminostatin derivatives for the treatment of arthrosis |
| AU2013307688A1 (en) * | 2012-08-29 | 2015-04-09 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
-
2014
- 2014-07-07 WO PCT/EP2014/001861 patent/WO2015018472A1/de not_active Ceased
- 2014-07-07 CN CN201480044142.6A patent/CN105451754A/zh active Pending
- 2014-07-07 AU AU2014304950A patent/AU2014304950B2/en not_active Ceased
- 2014-07-07 US US14/910,317 patent/US9750784B2/en not_active Expired - Fee Related
- 2014-07-07 JP JP2016532244A patent/JP6336067B2/ja not_active Expired - Fee Related
- 2014-07-07 CA CA2920420A patent/CA2920420C/en active Active
- 2014-07-07 EP EP14741803.2A patent/EP3030250B1/de active Active
- 2014-07-07 ES ES14741803T patent/ES2759060T3/es active Active
-
2016
- 2016-02-04 IL IL243983A patent/IL243983B/en active IP Right Grant
-
2017
- 2017-06-16 US US15/624,777 patent/US20170348380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124878T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
| EA202190115A1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| WO2015120110A3 (en) | Novel pharmaceutical formulations | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014526503A5 (enExample) | ||
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| WO2017091767A3 (en) | Drug formulations for cancer treatment | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015502926A5 (enExample) | ||
| JP2017512194A5 (enExample) | ||
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| EA202192322A1 (ru) | Фармацевтические составы | |
| JP2017507142A5 (enExample) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| JP2016515550A5 (enExample) | ||
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| JP2016512247A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2014148552A5 (enExample) |